Literature DB >> 8474379

Anabolic steroid abuse and cardiac death.

M C Kennedy1, C Lawrence.   

Abstract

OBJECTIVE: To examine the relationship between anabolic steroid abuse and cardiac death. We report the first two cases in Australia. They are the only reported cases in which the anabolic steroid oxymesterone has been detected. This compound has never been approved for use in Australia. CLINICAL FEATURES: Two footballers, aged 18 and 24, sustained fatal cardiac arrests while at training sessions. Both were considered fit and healthy. OUTCOME: Autopsy revealed features of a hypertrophic cardiomyopathy in the 18-year-old; the 24-year-old had findings of a myocarditis. In both cases the coronary arteries were normal and there was no evidence of coronary thrombosis. Urine in both subjects contained the anabolic steroid oxymesterone.
CONCLUSIONS: There are limited clinical uses for anabolic steroids but they are widely abused by athletes in attempts to alter lean body mass and strength. Acute non-fatal myocardial infarction was first reported in 1988 and fatal myocardial infarction in 1990. While a causal relationship is hard to prove, it is possible that the anabolic steroid contributed to the increase in cardiac size in the first subject and may have increased his responsiveness to catecholamines causing an arrhythmogenic event. In the second, the inflammatory changes could have provided the focus for an arrhythmia. It would appear that anabolic steroid abuse should be considered in any athlete presenting with an acute vascular event.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474379     DOI: 10.5694/j.1326-5377.1993.tb121797.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  19 in total

1.  Gym and tonic: a profile of 100 male steroid users.

Authors:  N A Evans
Journal:  Br J Sports Med       Date:  1997-03       Impact factor: 13.800

Review 2.  Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2008-07-02       Impact factor: 4.492

3.  Cardiac autonomic dysfunction in rats chronically treated with anabolic steroid.

Authors:  Pedro P Pereira-Junior; Elen A Chaves; Ricardo H Costa-E-Sousa; Masako O Masuda; Antonio C Campos de Carvalho; José H M Nascimento
Journal:  Eur J Appl Physiol       Date:  2005-12-13       Impact factor: 3.078

Review 4.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 5.  Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm.

Authors:  Suraj Achar; Armand Rostamian; Sanjiv M Narayan
Journal:  Am J Cardiol       Date:  2010-09-15       Impact factor: 2.778

6.  Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction.

Authors:  Aaron L Baggish; Rory B Weiner; Gen Kanayama; James I Hudson; Michael H Picard; Adolph M Hutter; Harrison G Pope
Journal:  Circ Heart Fail       Date:  2010-04-27       Impact factor: 8.790

7.  Identifying the aetiology of left ventricular hypertrophy in an athlete: importance of lifestyle modification.

Authors:  Miriam Jane Ball; Niall Keenan; Mary Lynch; Sanjay Prasad; Diana A Gorog
Journal:  BMJ Case Rep       Date:  2009-12-01

Review 8.  Medical issues associated with anabolic steroid use: are they exaggerated?

Authors:  Jay R Hoffman; Nicholas A Ratamess
Journal:  J Sports Sci Med       Date:  2006-06-01       Impact factor: 2.988

Review 9.  Testosterone, myocardial function, and mortality.

Authors:  Vittorio Emanuele Bianchi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 10.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.